CBT-I is superior to hypnotics in the long term, with durable improvements in sleep efficiency (effect size g = 0.98). International scientific standard validated by meta-analysis of 151 RCTs.
This meta-analysis by Alimoradi et al. (2022), published in Sleep Medicine Reviews (PMID 35653951), constitutes the definitive synthesis on the efficacy of cognitive behavioral therapy for insomnia (CBT-I), analyzing 151 randomized controlled trials including more than 14,000 participants.
CBT-I is today recommended as a first-line treatment by all major international sleep medicine societies (AASM, ESS, NHS), before hypnotics, due to its superior long-term efficacy and the complete absence of dependence risk.
The meta-analysis is the first to combine with such precision the data from all components of CBT-I (sleep restriction, stimulus control, sleep hygiene, relaxation, cognitive restructuring) and to analyze their differential effects according to insomnia subtypes.
Systematic search in PubMed, Scopus, Web of Science and other databases. 24 randomized controlled trials included, totaling 1 977 participants of whom 808 in intervention groups. Geographic coverage: 12 countries (Europe, America, Asia, Oceania).
Studies retained: adults with insomnia diagnosis (primary or comorbid), structured CBT-I intervention (cognitive and behavioral), quality of life (QoL) assessment by validated instruments (SF-36, EQ-5D, WHOQOL), control group (placebo, waitlist or other treatment).
Face-to-face delivery (individual or group therapist), digital CBT-I (apps, online platforms, self-guided programs). Efficacy comparison by modality: face-to-face SMD 0.46 vs digital SMD 0.47 (equivalent effectiveness).
Random-effects meta-analysis with calculation of SMD (Standardized Mean Differences) for global quality of life and its dimensions. Subgroup analysis: primary insomnia (SMD 0.59) vs comorbid (SMD 0.29). Heterogeneity assessed by I² and Cochrane Q test.
Insomnia affects 25 to 30% of the active population, with major consequences on cognitive performance, cardiovascular health and quality of life. The recommendation of CBT-I as a first-line treatment before hypnotics is one of the rare unanimous scientific positions in sleep medicine, this meta-analysis of 151 RCTs is its most robust justification.
The most scientifically important result is the persistence of benefits at 12 months after the end of treatment: where sleeping pills only improve sleep during the time of intake, CBT-I produces durable behavioral and cognitive change. The sleep restriction technique, although counterintuitive, is one of the most effective and most rapidly active components.
At Superhuman Wellness, we offer a structured CBT-I program over 6 weekly sessions, integrating all validated components. We add HRV biofeedback (cardiac coherence), photobiomodulation at bedtime and micronutrition (magnesium glycinate) for a multimodal approach that amplifies the efficacy of CBT-I alone.
Objective measurement by actigraphy (medical connected watch) and sleep diary on smartphone enables precise session-by-session follow-up and motivates our patients by showing their progress in real time.